Patents by Inventor Kristen M. Smith
Kristen M. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190389964Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.Type: ApplicationFiled: June 21, 2019Publication date: December 26, 2019Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
-
Patent number: 10358500Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.Type: GrantFiled: December 14, 2016Date of Patent: July 23, 2019Assignee: BIONOMICS INC.Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
-
Publication number: 20170114145Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.Type: ApplicationFiled: December 14, 2016Publication date: April 27, 2017Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
-
Patent number: 9631024Abstract: Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.Type: GrantFiled: June 17, 2015Date of Patent: April 25, 2017Assignee: Bionomics, Inc.Inventors: Christopher L. Reyes, Kristen M. Smith, Peter Chu, Lioudmila A. Campbell, Eric Ailor
-
Patent number: 9546214Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.Type: GrantFiled: April 2, 2015Date of Patent: January 17, 2017Assignee: Bionomics, Inc.Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
-
Publication number: 20160046723Abstract: Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.Type: ApplicationFiled: June 17, 2015Publication date: February 18, 2016Inventors: Christopher L. Reyes, Kristen M. Smith, Peter Chu, Lioudmila A. Campbell, Eric Ailor
-
Publication number: 20160031984Abstract: Disclosed herein are humanized anti-LGR5 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for the biding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.Type: ApplicationFiled: April 2, 2015Publication date: February 4, 2016Inventors: Christopher L. Reyes, Peter Chu, Kristen M. Smith, Lioudmila A. Campbell, Farbod Shojaei, John Thomas Norton
-
Publication number: 20100105574Abstract: Disclosed are enriched preparations of neuroblastoma tumor initiating cells (NB TICs). The NB TICs are capable of self-renewal, initiating neuroblastoma tumor growth in vivo and are capable of being passaged in high frequency. These NB TICs have chromosomal abnormalities and are capable of giving rise to secondary tumor spheres. Methods are also disclosed for preparing the enriched preparations of NB TICs, such as from neuroblastoma tumor tissue and metastasized bone marrow. Also disclosed are methods of screening candidate substances to identify therapeutic agents for the treatment of neuroblastoma. Methods are also provided for screening a sample for neuroblastoma, as well as for screening a sample to identify the stage of neuroblastoma present. Kits are also provided for selecting appropriate anti-neuroblastoma compounds for a patient, and utilize isolated compositions of the patients' neuroblastoma tumor initiating cells. In this manner, a customized medicinal profile for the patient may be devised.Type: ApplicationFiled: October 29, 2009Publication date: April 29, 2010Applicant: HOSPITAL FOR SICK CHILDRENInventors: Leon M. Hansford, Kristen M. Smith, Alessandro Datti, Freda M. Miller, David R. Kaplan
-
Patent number: 7632678Abstract: Disclosed are enriched preparations of neuroblastoma tumor initiating cells (NB TICs). The NB TICs are capable of self-renewal, initiating neuroblastoma tumor growth in vivo and are capable of being passaged in high frequency. These NB TICs have chromosomal abnormalities and are capable of giving rise to secondary tumor spheres. Methods are also disclosed for preparing the enriched preparations of NB TICs, such as from neuroblastoma tumor tissue and metastasized bone marrow. Also disclosed are methods of screening candidate substances to identify therapeutic agents for the treatment of neuroblastoma. Methods are also provided for screening a sample for neuroblastoma, as well as for screening a sample to identify the stage of neuroblastoma present. Kits are also provided for selecting appropriate anti-neuroblastoma compounds for a patient, and utilize isolated compositions of the patients' neuroblastoma tumor initiating cells. In this manner, a customized medicinal profile for the patient may be devised.Type: GrantFiled: November 22, 2006Date of Patent: December 15, 2009Assignee: The Hospital for Sick ChildrenInventors: Loen M. Hansford, Kristen M. Smith, Alessandro Datti, Freda M. Miller, David R. Kaplan
-
Publication number: 20090036387Abstract: Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that include these chemical entities are also provided for the treatment of neuroblastoma. These pharmaceutical preparations are suitable for the treatment of humans, and are particularly suited for the treatment of children of 12 years of age or younger having neuroblastoma. The compositions and pharmaceutical preparations posses reduced normal cell cytotoxicity. The compositions and pharmaceutical preparations may be used alone or together with other conventional neuroblastoma preparations as part of a clinical regimen in the treatment and management of neuroblastoma.Type: ApplicationFiled: September 9, 2008Publication date: February 5, 2009Applicant: The Hospital for Sick ChildrenInventors: DAVID R. KAPLAN, Kristen M. Smith, Alessandro Datti
-
Publication number: 20080038770Abstract: Disclosed are enriched preparations of neuroblastoma tumor initiating cells (NB TICs). The NB TICs are capable of self-renewal, initiating neuroblastoma tumor growth in vivo and are capable of being passaged in high frequency. These NB TICs have chromosomal abnormalities and are capable of giving rise to secondary tumor spheres. Methods are also disclosed for preparing the enriched preparations of NB TICs, such as from neuroblastoma tumor tissue and metastasized bone marrow. Also disclosed are methods of screening candidate substances to identify therapeutic agents for the treatment of neuroblastoma. Methods are also provided for screening a sample for neuroblastoma, as well as for screening a sample to identify the stage of neuroblastoma present. Kits are also provided for selecting appropriate anti-neuroblastoma compounds for a patient, and utilize isolated compositions of the patients' neuroblastoma tumor initiating cells. In this manner, a customized medicinal profile for the patient may be devised.Type: ApplicationFiled: November 22, 2006Publication date: February 14, 2008Applicant: Hospital For Sick ChildrenInventors: Loen M. Hansford, Kristen M. Smith, Alessandro Datti, Freda M. Miller, David R. Kaplan